The rationale for using ATX as a potential therapeutic target is based on reports that ATX is over expressed in various cancers including glioblastoma (38), lung cancer (47, 48), and breast cancer (49), and that its activity contributes to its invasiveness and tumorigenesis. Here, ENPP2 is linked to breast carcinoma.